Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Ticker
PGEN
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$1.60B
52-week range
$3.04 - $8.98
Valuation
Share price
$4.47 (close of Nov 6, 2026)
P/E (TTM)
60.90x
Price to book
19.13x
Price to free cash flow
-21.57x
Enterprise value
$1.65B
Book value per share
$0.23
Price performance
Period
Change
1 day
+5.92%
5 days
-35.59%
1 month
-40.79%
3 months
-35.31%
6 months
+1.59%
Year to date
+6.94%
1 year
+14.03%
3 years
+285.34%
5 years
-12.52%
10 years
-82.23%
All time
-81.09%
Short interest
As of
Oct 15, 2026
Short % of float
23.84%
Shares short
46.39M
Days to cover
10.21
Change since prior report
-2.43%
Source
FINRA consolidated short interest
Profitability and growth
Return on invested capital
-92.71%
Return on assets
-161.18%
Return on capital employed
-93.49%
Gross margin
9.85%
Net margin
-2,588.21%
EBITDA margin
-1,108.10%
Revenue growth
146.73%
Cash flow and balance sheet
Free cash flow yield (TTM)
-4.64%
Current ratio
5.58x
Net debt to EBITDA
1.17x
Latest reported year
Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$9.68M
Cost of revenue
$8.73M
Gross profit
$954.00K
EBITDA
-$107.31M
Net income
-$250.64M
Earnings per share
$-1.37
Research and development
$41.33M
Interest expense
$3.87M
Shares outstanding
312.98M
Income statement by year
Period end
Revenue
Gross profit
Net income
EPS
2025-12-31
$9.68M
$954.00K
-$250.64M
-$1.37
2024-12-31
$3.92M
-
-$126.23M
-$0.47
2023-12-31
$6.22M
-
-$95.90M
-$0.39
2022-12-31
-
-
$28.32M
$0.14
2021-12-31
$14.27M
-
-$92.17M
-$0.47
2020-12-31
$31.99M
-
-$170.52M
-$1.02
2019-12-31
$90.72M
-
-$322.32M
-$2.09
2018-12-31
$151.18M
$36.78M
-$509.34M
-$3.93
2017-12-31
$230.98M
$151.42M
-$117.02M
-$0.98
2016-12-31
$190.93M
$129.29M
-$186.61M
-$1.58
Margins and returns by year
Period end
Gross margin
Net margin
Return on equity
Return on capital
2025-12-31
9.85%
-2,588.21%
-
-92.71%
2024-12-31
-
-3,216.18%
-
-
2023-12-31
-
-1,540.63%
-80.93%
-79.06%
2022-12-31
-
-
22.43%
-44.90%*
2021-12-31
-
-646.01%
-85.86%
-37.26%*
2020-12-31
-
-533.01%
-253.85%
-41.87%*
2019-12-31
-
-355.29%
-
-56.32%*
2018-12-31
24.33%
-336.91%
-134.49%
-83.02%
2017-12-31
65.56%
-50.66%
-21.41%
-24.86%
2016-12-31
67.72%
-97.74%
-32.78%
-21.01%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.